| Market Cap | 17.64M | P/E | - | EPS this Y | 55.80% | Ern Qtrly Grth | - |
| Income | -32.79M | Forward P/E | -0.84 | EPS next Y | 68.80% | 50D Avg Chg | -36.00% |
| Sales | 2.87M | PEG | -0.01 | EPS past 5Y | - | 200D Avg Chg | -45.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 59.10% | 52W High Chg | -77.00% |
| Recommedations | 2.30 | Quick Ratio | 0.05 | Shares Outstanding | 25.97M | 52W Low Chg | 19.00% |
| Insider Own | 40.26% | ROA | -101.84% | Shares Float | 17.25M | Beta | 1.37 |
| Inst Own | 10.24% | ROE | - | Shares Shorted/Prior | 196.23K/96.97K | Price | 0.68 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 816,460 | Target Price | 10.50 |
| Oper. Margin | -1,086.39% | Earnings Date | Mar 29 | Volume | 1,375,999 | Change | -4.35% |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
| Maxim Group | Hold | Aug 16, 22 |
| HC Wainwright & Co. | Buy | Jul 20, 21 |
| H.C. Wainwright | Buy | May 15, 20 |
| Roth Capital | Buy | Feb 19, 20 |
| H.C. Wainwright | Buy | Dec 30, 19 |
| Northcoast Research | Outperform | Sep 10, 18 |
| Laidlaw & Co. | Buy | Sep 10, 18 |
| Cantor Fitzgerald | Overweight | Sep 10, 18 |